✂ Fed’s first rate cut since 2020: Use our free Stock Screener to find new opportunities fastExplore for FREE

London stocks edge lower ahead of PMI data

Published 09/23/2024, 03:52 AM
Updated 09/23/2024, 03:56 AM
© Reuters. FILE PHOTO: Signage for the London Stock Exchange Group is seen outside of offices in Canary Wharf in London, Britain, August 3, 2023. REUTERS/Toby Melville/File Photo
UK100
-
BRBY
-
FTMC
-
AZN
-
RTMVY
-

(Reuters) - UK shares slipped on Monday after logging their worst day since August in the previous session, while investors awaited flash PMI data for more clues on the country's economic growth.

At 0720 GMT, the blue-chip FTSE 100 and the more domestically-focused midcap index were down 0.1%, each.

Both indexes notched their worst day in nearly seven weeks on Friday, after the Bank of England held interest rates steady on Thursday, even as the Federal Reserve cut benchmark rates by an outsized 50 basis points.

Investors will eye UK flash PMI data later in the day for the services and manufacturing sectors for more indicators for growth and price increases in these sectors.

Last week, Britain's consumer price inflation data - which is closely watched by the BoE for its monetary policy - pointed to persistent price pressures in the services sector.

Precious metal miners rose 0.8% as gold prices scaled record highs, driven by Fed rate cuts and demand for the safe-haven asset on geopolitical risks in the Middle East.

The personal goods sector led declines, dragged by a 2.2% loss in shares of luxury goods maker Burberry, which was on track for a second straight session in the red.

© Reuters. FILE PHOTO: Signage for the London Stock Exchange Group is seen outside of offices in Canary Wharf in London, Britain, August 3, 2023. REUTERS/Toby Melville/File Photo

Rightmove (OTC:RTMVY) jumped 3% after Australia's REA Group made a third pitch to buy the UK property-listing firm with a new 6.1 billion pound ($8.12 billion) offer.

AstraZeneca (NASDAQ:AZN) slipped 0.6% after the drugmaker said its experimental precision drug did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.